Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

A cellular housekeeping process where cells break down and recycle damaged components. Declines with age and is stimulated by fasting.

What is Intermittent fasting?

An eating pattern that cycles between periods of fasting and eating. Various protocols (16:8, 5:2) are studied for metabolic, cardiovascular, and longevity benefits.

What is Zone 2 cardio?

Low-intensity aerobic exercise performed at roughly 60–70% of maximum heart rate, primarily using the aerobic energy system. Associated with mitochondrial health and longevity.

Geographic regions identified by researchers where people consistently live longer and healthier lives than average, including Sardinia, Okinawa, and Loma Linda.

"New Eye Treatment Could Change Vision Care for Aging Adults"

EyePoint, Inc. has announced its participation in several upcoming healthcare conferences where company leaders will discuss their innovative treatments for serious retinal diseases. These events include the Stifel 2026 Virtual Ophthalmology Forum on May 26, the Jefferies Global Healthcare Conference on June 3, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9. Interested individuals can access live webcasts and recordings of these discussions on EyePoint’s website.

EyePoint is focused on developing advanced therapies for conditions like wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Their lead product, DURAVYU™, is an investigational treatment that uses a sustained delivery system to release vorolanib, a medication designed to target specific pathways involved in retinal diseases. This treatment is currently undergoing Phase 3 clinical trials, with results for wet AMD expected in mid-2026. If successful, DURAVYU could significantly improve vision and quality of life for people suffering from these debilitating eye conditions.

While the research surrounding DURAVYU is promising, it’s important to note that it is still in the testing phase and has not yet received FDA approval. The timeline for potential approval remains uncertain. EyePoint has a history of innovation in the field, having developed four approved drugs over the past three decades, and aims to continue improving patient outcomes in retinal health.

For those interested in eye health, staying informed about new treatments like DURAVYU could be beneficial, especially as these advancements may lead to better management of age-related eye conditions in the future.

Source: globenewswire.com